

Gary R. Feldman, MD, FACR
President

January 24, 2024

Madelaine A. Feldman, MD, FACR
VP, Advocacy & Government Affairs

Iowa State Capitol
1007 East Grand Avenue
Des Moines, Iowa 50319

Michael Saitta, MD, MBA
Treasurer

Aaron Broadwell, MD
Secretary

Erin Arnold, MD
Director

Leyka M. Barbosa, MD, FACR
Director

Kostas Botsoglou, MD
Director

Michael S. Brooks, MD, FACP, FACR
Director

Amish J. Dave, MD, MPH
Director

Harry Gewanter, MD, FAAP, MACR
Director

Adrienne R. Hollander, MD
Director

Firas Kassab, MD, FACR
Director

Robert W. Levin, MD
Director

Amar Majjhoo, MD
Director

Gregory W. Niemer, MD
Director

Joshua Stolow, MD
Director

HEADQUARTER OFFICE

Ann Marie Moss
Executive Director

Re: Support for HF 626

The Coalition of State Rheumatology Organizations (CSRO) is a national organization composed of over 30 state and regional professional rheumatology societies, including our member society that represents providers of rheumatology care in Iowa. CSRO was formed by physicians to ensure excellence and access to the highest quality care for patients with rheumatologic, autoimmune, and musculoskeletal disease. It is with this in mind that we write to you in support of HF 626.

As you consider HF 626, CSRO would like to convey its support for providing continuity of care to stable patients.

Non-medical switching occurs when health plans and Pharmacy Benefit Managers (PBMs) force a stable patient to switch from their currently effective medication by restricting coverage for that medication. Health plans and pharmacy benefit managers accomplish this by: removing the drug from their formulary, moving the drug to a more restrictive formulary tier, or using other prevailing means to increase the patient's out-of-pocket costs for the drug or restrict access.

Patients that suffer from complex chronic conditions, such as rheumatoid arthritis and many others, require continuity of care to successfully manage their condition. The aforementioned conditions are extremely complex and present in a variety of ways, necessitating a high degree of individualized and attentive care.

Physicians may spend months or years of trial and error finding a treatment regimen that properly manages their condition. The resulting course of treatment must carefully balance each patient's unique medical history, comorbid conditions, and side-effect balancing drug interactions. This equilibrium is carefully chosen and tenuous. Even slight deviations in treatment and variations between drugs, even those in the same therapeutic class, can cause serious adverse events. Aside from needless suffering, the resulting disease progression can be irreversible, life threatening, and cause the patient's original treatment to lose effectiveness. It cannot be assumed that a treatment that works for *one patient* will work for *each patient*. Non-medical switches are one-size fits all decisions that disrupt physicians' ability to exercise their medical expertise in concert with their patients.

Gary R. Feldman, MD, FACP
President

Madelaine A. Feldman, MD, FACP
VP, Advocacy & Government Affairs

Michael Saitta, MD, MBA
Treasurer

Aaron Broadwell, MD
Secretary

Erin Arnold, MD
Director

Leyka M. Barbosa, MD, FACP
Director

Kostas Botsoglou, MD
Director

Michael S. Brooks, MD, FACP, FACP
Director

Amish J. Dave, MD, MPH
Director

Harry Gewanter, MD, FAAP, MACR
Director

Adrienne R. Hollander, MD
Director

Firas Kassab, MD, FACP
Director

Robert W. Levin, MD
Director

Amar Majjhoo, MD
Director

Gregory W. Niemer, MD
Director

Joshua Stolow, MD
Director

HEADQUARTER OFFICE

Ann Marie Moss
Executive Director

It must be noted that CSRO is not unconcerned with the cost of pharmaceuticals in the United States. However, non-medical switching is a poor way to control costs for the patient populations in question, and can lead to larger follow-on costs that swamp any up-front savings. Physicians, pharmacists, and other healthcare administrators have reported that nonmedical switching increases administrative time, increases side effects or new unforeseen effects, and increases downstream costs to plans.¹ Moreover, when a stable plan enrollee is switched for nonmedical reasons, their care is more likely to be interrupted by a second switch.² These cost-motivated switches increase plan enrollees' health care utilization, disrupt the course of care, and, as a result, increase related health care costs.³

For these reasons, CSRO requests your support for HF 626. We appreciate your consideration of our comments.

Respectfully,



Gary Feldman, MD, FACP
President
Board of Directors



Madelaine A. Feldman, MD, FACP
VP, Advocacy & Government Affairs
Board of Directors

¹ *E.g.*, D.T. Rubin, et al., P354 Analysis of Outcomes After Non-Medical Switching of Anti-Tumor Necrosis Factor Agents, EUR. CROHN'S & COLITIS ORGANISATION (2015), <https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p354-analysis-of-outcomes-after-non-medical-switching-of-anti-tumor-necrosis-factor-agents.html>. Bryan R. Cote & Elizabeth A. Petersen, Impact of Therapeutic Switching in Long-Term Care, 14 AM. J. MANAGED CARE SP23 (2008).

² *Cost-Motivated Treatment Changes: Implications for Non-Medical Switching*, Institute for Patient Access (Oct. 2016), http://allianceforpatientaccess.org/wp-content/uploads/2016/10/IfPA_Cost-Motivated-Treatment-Changes_October-2016.pdf.

³ *Id.*